Secretory Products of the Human GI Tract Microbiome and Their Potential Impact on Alzheimer's Disease (AD): Detection of Lipopolysaccharide (LPS) in AD Hippocampus.
Zhao Y, Jaber V, Lukiw WJ. · 2017
Read Secretory Products of the Human GI Tract Microbiome and Their Potential Impact on Alzheimer's Disease (AD): Detection of Lipopolysaccharide (LPS) in AD Hippocampus. by Zhao Y, Jaber V, Lukiw WJ. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5504724.txt.
Introduction
Zhao, Jaber, and Lukiw present a Perspectives piece in Frontiers in Cellular and Infection Microbiology. It asks whether gut bacteria help drive Alzheimer's disease. Common gut bacteria release a toxin called LPS. Once outside the gut, such toxins can inflame the brain. The authors measured LPS in donated brain tissue.
Alzheimer's brains held two to three times more LPS than matched controls, they report. Some advanced cases showed up to 26-fold higher levels. The hippocampus, a memory hub, was among the regions sampled. The piece links these findings to wider work on gut-to-brain signals. It urges care in reading cause from such early clues.
Catalog record
| CREATOR | Zhao Y, Jaber V, Lukiw WJ. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Secretory Products of the Human GI Tract Microbiome and Their Potential Impact on Alzheimer's Disease (AD): Detection of Lipopolysaccharide (LPS) in AD Hippocampus By Yuhai Zhao, Vivian Jaber, Walter J Lukiw Published in: Frontiers in Cellular and Infection Microbiology DOI: 10.3389/fcimb.2017.00318 ABSTRACT Abstract Although the potential contribution of the human gastrointestinal (GI) tract microbiome to human health, aging, and disease is becoming increasingly acknowledged, the molecular mechanics and signaling pathways of just how this is accomplished is not well-understood. Major bacterial species of the GI tract, such as the abundant Gram-negative bacilli Bacteroides fragilis (B. fragilis) and Escherichia coli (E. coli), secrete a remarkably complex array of pro-inflammatory neurotoxins which, when released from the confines of the healthy GI tract, are pathogenic and highly detrimental to the homeostatic function of neurons in the central nervous system (CNS). For the first time here we report the presence of bacterial lipopolysaccharide (LPS) in brain lysates from the hippocampus and superior temporal lobe neocortex of Alzheimer's disease (AD) brains. Mean LPS levels varied from two-fold increases in the neocortex to three-fold increases in the hippocampus, AD over age-matched controls, however some samples from advanced AD hippocampal cases exhibited up to a 26-fold increase in LPS over age-matched controls. This “Perspectives” paper will further highlight some very recent research on GI tract microbiome signaling to the human CNS, and will update current findings that implicate GI tract microbiome-derived LPS as an important internal contributor to inflammatory degeneration in the CNS. Keywords: 42 amino acid amyloid-beta (Aβ42) peptide, Alzheimer's disease (AD), Bacteriodetes fragilis (B. fragilis), Escherichia coli (E. coli), lipopolysaccharide (LPS), microbiome, small non-coding RNAs (sncRNAs), thanatomicrobiome INTRODUCTION: THE HUMAN GI TRACT MICROBIOME The human GI tract is fundamentally a highly vascularized and extensively innervated, columnar epithelial-cell lined tube about 9 m (30 feet) in length that consists of the stomach, small intestine (duodenum, jejunum, and ileum) and large intestine (cecum, colon, rectum, and anal canal; Reinus and Simon, 2014). Each anatomical region of this tubular structure harbors a complex and dynamic microbiome, containing ~1,000 different species of anaerobic or facultative anaerobic bacteria that appear to be characteristic for that GI tract segment. Indeed, the dynamism of the GI tract microbiome along its length is in part reflected by the abundance, speciation, complexity and stoichiometry of individual resident bacterial species. In addition to the major bacterial component of the GI tract are microbial eukaryotes, archaea, fungi, protozoa, viruses, and other commensal microorganisms which make up the remainder. Together with host cells these jointly comprise the complete metaorganism: (i) whose symbiotic associations and interactions are indispensable for homeostatic physiological functions in human health; and (ii) which exhibit alterations in composition in response to dietary factors, developmental stage, GI tract disturbances, aging, and neurological disorders, including AD (Bhattacharjee and Lukiw, 2013; Hill et al., 2014; Perez et al., 2014; Potgieter et al., 2015; Zhao and Lukiw, 2015; Alkasir et al., 2016; Ghaisas et al., 2016; Hu et al., 2016; Lukiw, 2016; Pistollato et al., 2016; Scheperjans, 2016). GI TRACT BACTERIAL MICROBIOME—EXUDATES AND SECRETORY PRODUCTS Two large prokaryotic classes of Bacteria (or “Eubacteria”) and Archaea (or “Archaeobacteria”) have been recently reclassified (as of 10/2016) into 35 phyla (http://www.bacterio.net/-classifphyla.html) or major bacterial divisions. Interestingly the GI tract microbiome of Homo sapiens has co-evolved with just two major phyla: Bacteriodetes, which make up ~20% of all GI tract bacteria, and Firmicutes, which make up ~80% of all GI tract bacteria; with Actinobacteria (~3%), Proteobacteria (~1%), and Verrumicrobia (~0.1%) making up significantly smaller fractions. These five bacterial groups appear to constitute the essential “core” of the human GI tract microbiome (http://www.bacterio.net/-classifphyla.html; Zhao et al., 2015; Hug et al., 2016; Lloyd-Price et al., 2016; Sender et al., 2016). The vast proportion of all GI tract microbiota consists of anaerobic or facultative anaerobic bacteria (Bhattacharjee and Lukiw, 2013; Heintz and Mair, 2014; Köhler et al., 2016; Lloyd-Price et al., 2016). For example, although variable, the obligate anaerobe Bacteroides fragilis (B. fragilis; phyla Bacteroidetes) and the facultative anaerobe Escherichia coli (E. coli; phyla Proteobacteria): (i) together constitute ~35–40 percent of all GI tract bacteria; (ii) are the most abundant Gram-negative bacilli of the middle and lower colon, respectively, of the human GI tract; and (iii) constitute about ~30–50 percent of the dry weight of fecal matter. B. fragilis or E. coli require about 20 min to divide under optimal conditions of commensal bacterial growth, and unless special biophysical processes of growth dynamics are in operation (such as dormancy, hibernation, spore formation, etc.) have a life span of up to several hours (Choi and Cho, 2016; Pinti et al., 2016; Todar, 2016). Interestingly, species of the obligate anaerobe Bacteroides such as B. fragilis display remarkably diverse antibiotic resistance mechanisms and exhibit the highest resistance rates of any anaerobic pathogen. This includes an inherent high-level resistance to penicillin through their ability to produce beta-lactamase enzymes which endow them with multiple resistance to β-lactam antibiotics such as penicillin and cephamycin (Ayala et al., 2005; Bush and Bradford, 2016; Hu et al., 2016). Specific species of Bacteroidetes such as Bacteroides fragilis (B. fragilis), normally an abundant commensal microorganism of the middle GI tract, are known to be generally beneficial to human health through their ability to digest dietary fiber and related dietary fiber precursors containing substances such as cellulose, lignin, and pectin, which are normally resistant to the action of host digestive enzymes. Dietary fibers are catabolized into digestible short-chain fatty acids (SCFAs), volatile fatty acids and polysaccharides in part through the biosynthetic capability of this GI tract abundant bacillus (Keenan et al., 2016; Scheperjans, 2016). When B. fragilis escapes the highly compartmentalized microbe-dense environment of the GI tract (1011 microbes per gram of fecal matter), they can induce substantial systemic inflammatory pathology with significant sickness, morbidity and mortality (Choi et al., 2016; Fathi and Wu, 2016; Cattaneo et al., 2017; Shivaji, 2017). Enterotoxigenic strains of B. fragilis have been associated with bacteremia, colitis, diarrhea, sepsis, systemic infection, and the development of GI tract cancers and neurological disorders, including AD, that have an increased incidence with aging (Choi et al., 2016; Fathi and Wu, 2016; Keenan et al., 2016; Scheperjans, 2016). Interestingly, certain species of Bacteroidetes have been recently shown to propagate in animal models fed high fat-cholesterol (HFC) diets deprived of sufficient intake of dietary fiber; this suggests that sufficient dietary fiber may have a significant role in regulating the abundance, complexity and stoichiometry of certain species in the GI tract microbiome, including B. fragilis (Heinritz et al., 2016; Köhler et al., 2016; Pistollato et al., 2016; unpublished observations). In addition to these positive health benefits however, these vast numbers of human GI tract resident Gram-negative bacilli when stressed secrete prodigious quantities of endotoxins, exotoxins, endotoxins, exotoxins, lipooligosacahrides (LOSs) and lipopolysaccharides (LPSs), amyloids, and small non-coding RNAs (sncRNAs; see below and Figure 1). [Figure: Like other Gram-negative bacilli, the gastrointestinal (GI) tract abundant Bacteroides fragilis (micrograph of B. fragilis shown; original photo courtesy of Rosa Rubicondior; (http://rosarubicondior.blogspot.com/2014/11/evolving-cooperation-but-for-who-or-what.html) is capable, when stressed, of releasing a broad spectrum of highly neurotoxic, pro-inflammatory and potentially pathogenic molecules; these comprise five major classes of secreted molecules and include endotoxins, exotoxins, lipooligosacahride (LOS) and lipopolysaccharide (LPS), amyloids, and small non-coding RNAs (sncRNA).